NewEdge Advisors’s Gilead Sciences GILD Stock Holding History

NewEdge Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$54.7M	Buy	392,435 +231,715	+144%	+$32.4M	0.2%	103
2025 Q4	$19.7M	Buy	160,720 +1,637	+1%	+$199K	0.07%	253
2025 Q3	$17.7M	Buy	159,083 +52,594	+49%	+$5.98M	0.08%	247
2025 Q2	$11.8M	Buy	106,489 +11,903	+13%	+$1.27M	0.06%	328
2025 Q1	$10.6M	Buy	94,586 +2,933	+3%	+$303K	0.06%	303
2024 Q4	$8.47M	Buy	91,653 +35,657	+64%	+$3.21M	0.05%	347
2024 Q3	$4.69M	Buy	55,996 +878	+2%	+$67K	0.03%	495
2024 Q2	$3.78M	Sell	55,118 -5,307	-9%	-$354K	0.03%	534
2024 Q1	$4.43M	Sell	60,425 -1,038	-2%	-$79.8K	0.04%	424
2023 Q4	$4.94M	Buy	61,463 +2,235	+4%	+$174K	0.05%	355
2023 Q3	$4.44M	Sell	59,228 -3,749	-6%	-$288K	0.05%	350
2023 Q2	$4.85M	Buy	62,977 +15,049	+31%	+$1.2M	0.05%	325
2023 Q1	$3.95M	Buy	47,928 +10,554	+28%	+$874K	0.05%	346
2022 Q4	$1.71M	Buy	37,374 +7,552	+25%	+$598K	0.05%	360
2022 Q3	$1.84M	Buy	29,822 +2,247	+8%	+$142K	0.03%	453
2022 Q2	$1.7M	Buy	27,575 +2,000	+8%	+$124K	0.03%	483
2022 Q1	$1.52M	Sell	25,575 -5,552	-18%	-$355K	0.02%	505
2021 Q4	$2.26M	Buy	31,127 +17,516	+129%	+$1.21M	0.03%	410
2021 Q3	$951K	Sell	13,611 -4,397	-24%	-$309K	0.02%	536
2021 Q2	$1.24M	Sell	18,008 -1,406	-7%	-$93.9K	0.03%	430
2021 Q1	$1.25M	Sell	19,414 -10,077	-34%	-$650K	0.04%	390
2020 Q4	$1.72M	Sell	29,491 -1,296	-4%	-$78.2K	0.06%	286
2020 Q3	$1.95M	Buy	30,787 +3,642	+13%	+$253K	0.07%	249
2020 Q2	$2.09M	Sell	27,145 -3,909	-13%	-$300K	0.08%	221
2020 Q1	$2.32M	Buy	31,054 +17,945	+137%	+$1.24M	0.11%	174
2019 Q4	$851K	Sell	13,109 -674	-5%	-$43.9K	0.03%	392
2019 Q3	$874K	Sell	13,783 -400	-3%	-$26.1K	0.04%	362
2019 Q2	$958K	Buy	14,183 +491	+4%	+$32.3K	0.06%	285
2019 Q1	$890K	Buy	13,692 +2,757	+25%	+$183K	0.06%	288
2018 Q4	$684	Buy	10,935 +3,627	+50%	+$254K	0.04%	304
2018 Q3	$564K	Sell	7,308 -1,105	-13%	-$83.5K	0.04%	330
2018 Q2	$600	Buy	8,413 +112	+1%	+$7.91K	0.05%	278
2018 Q1	$607K	Buy	8,301 +4,654	+128%	+$370K	0.07%	245
2017 Q4	$271K	Sell	3,647 -689	-16%	-$52.3K	0.04%	337
2017 Q3	$355K	Buy	4,336 +561	+15%	+$42.9K	0.06%	251
2017 Q2	$262K	Buy	+3,775	New	+$251K	0.04%	278
2016 Q4	–	Sell	-9,354	Closed	-$740K	–	270
2016 Q3	$740K	Buy	9,354 +5,572	+147%	+$453K	0.23%	89
2016 Q2	$313K	Buy	+3,782	New	+$336K	0.13%	124

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

NewEdge Advisors's GILD Position: Q1 2026 in Review

NewEdge Advisors increased its Gilead Sciences (GILD) stake by 144% in Q1 2026, buying an estimated $32.4M and bringing the position to 392,435 shares worth $54.7M. The position accounts for 0.2% of the portfolio, ranked #103.

NewEdge Advisors first reported a position in GILD in Q2 2016 and has held it in 38 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

NewEdge Advisors held 392,435 shares of Gilead Sciences worth $54.7M as of Q1 2026.
NewEdge Advisors bought 231,715 Gilead Sciences shares in Q1 2026, an estimated $32.4M.
Gilead Sciences made up 0.2% of NewEdge Advisors's portfolio in Q1 2026, its #103 holding.
NewEdge Advisors first reported a position in Gilead Sciences in Q2 2016 and has held it in 38 quarters since.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.